The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis

Journal of Rheumatology

Volumn 30, Issue 8, 2003, Pages 1691-1695

  Jansen, Louise M A ^b   Van Schaardenburg, Dirkjan ^b   Van Der Horst Bruinsma, Irene E ^a   Van De Stadt, Rob J ^b   De Koning, Margret H M T ^b   Dijkmans, Ben A C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Antibodies; Cyclic citrullinated peptide; Early prognosis; Rheumatoid arthritis; Undifferentiated polyarthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; PEPTIDE ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTHRITIS; ARTICLE; BACTERIAL ARTHRITIS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYSTAL; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; JOINT RADIOGRAPHY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; POLYARTHRITIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PSORIATIC ARTHRITIS; QUESTIONNAIRE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SPONDYLOARTHROPATHY; STATISTICAL ANALYSIS; SYMPTOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CITRULLINE; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 0042029646     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. van der Heijde DM, van Leeuwen MA, van Riel PLCM, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-32.
2. Hulsmans HMJ, Jacobs JWG, van der Heijde DMFM, van Albada Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43:1927-40.
3. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. The Lancet 1997;350:309-18.
4. Abu-Shakra M, Toker R, Flusser D, et al. Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease-modifying drugs. Arthritis Rheum 1998;41:1190-5.
5. van der Heijde DMFM, van Riel PL, van Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. The Lancet 1989;1036-8.
6. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
7. Saraux A, Berthelot JM, Chales G, et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 2001;44:2485-91.
8. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
9. Jansen LMA, van Schaardenburg D, van der Horst Bruinsma IE, Dijkmans BA. One year outcome of undifferentiated polyarthritis. Ann Rheum Dis 2002;61:700-3.
10. Leigh JP, Fries JF. Predictors of disability in a longitudinal sample of patients with rheumatoid arthritis. Ann Rheum Dis 1992;51:581-7.
11. Eberhardt KB, Fex E. Functional impairment and disability in early rheumatoid arthritis - development over 5 years. J Rheumatol 1995;22:1037-42.
12. van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective followup study of 147 patients. Br J Rheumatol 1992;31:519-25.
13. Eberhardt KB, Rydgren LC, Pettersson H, Wollheim FA. Early rheumatoid arthritis - onset, course, and outcome over 2 years. Rheumatol Int 1990;10(4):135-142.
14. van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis: results of a followup study [published erratum appears in J Rheumatol 1993 Dec;20:2179] [see comments]. J Rheumatol 1993;20:1288-96.
15. van der Heide A, Remme CA, Hofman DM, Jacobs JW, Bijlsma JW. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995;38:1466-74.
16. van der Heijde DM, van Leeuwen MA, van Riel PLCM, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-32.
17. Matsuda Y, Yamanaka H, Higami K, Kashiwazaki S. Time lag between active joint inflammation and radiological progression in patients with early rheumatoid arthritis. J Rheumatol 1998;25:427-32.
18. van-Leeuwen MA, van-Rijswijk MH, Sluiter WJ, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997;24:20-7.
19. Kroot EJA, de Jong BAW, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
20. Nienhuis RLF, Mandema E. A new serum factor in patients with rheumatoid arthritis, the antiperinuclear factor. Ann Rheum Dis 1964;23:302-5.
21. Hoet RM, Boerbooms AM, Arends M, Ruiter DJ, van Venrooij WJ. Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis 1991;50:611-8.
22. Westgeest AA, Boerbooms AM, Jongmans M, Vandenbroucke JP, Vierwinden G, van der Putte LB. Antiperinuclear factor indicator of more severe disease in seronegative rheumatoid arthritis. J Rheumatol 1987;14:893-7.
23. van Jaarsveld CHM, ter Borg EJ, Jacobs JWG, et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 1999;17:689-97.
24. Schellekens GA, Visser H, de Jong BAW, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
25. Jansen LMA, van der Horst Bruinsma IE, van Schaardenburg D, van de Stadt RJ, de Koning MHMT, Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002;29:2074-6.
26. Prevoo ML, van 't Hof M, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. modified disease activity scores that include twenty-eight joint counts: development and validation. Arthritis Rheum 1995;38:44-8.
27. Bijlsma JW, Oude Heuvel CHB, Zaalberg A. Development and validation of the Dutch questionnaire capacities of daily life (VDF) for patients with rheumatoid arthritis. J Rehabil Sci 1990;3:71-4.
28. Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002;46:913-20.
29. Hakala M, Niemine P, Koivisto O. More evidence from a community based series of better outcome in rheumatoid arthritis. Data on the effect of multidisciplinary care on the retention of functional ability. J Rheumatol 1994;21:1432-7.
30. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-43.
31. Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000;39:122-33.